Last reviewed · How we verify
ACD440
At a glance
| Generic name | ACD440 |
|---|---|
| Sponsor | AlzeCure Pharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- ACD440 Gel in Peripheral Neuropathic Pain (PHASE2)
- Study of Safety, Efficacy, and Pharmacokinetics of Topical ACD440 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ACD440 CI brief — competitive landscape report
- ACD440 updates RSS · CI watch RSS
- AlzeCure Pharma portfolio CI